While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

Cardiovascular disease remains one of the leading causes of mortality in the world, responsible for nearly 20 million deaths in 2022 alone. 

Medtronic confirmed its decision in a statement, but did not provide any specific details. The deal was originally announced in May.

Two separate studies examined the controversial topic of prescribing statins to high-risk elderly patients who do not already have high cholesterol or cardiovascular disease.

Researchers focused on 22 pairs of identical twins for 8 weeks, asking one twin to follow a healthy vegan diet and the other to follow a healthy omnivorous diet.

Roche, one of the world’s largest pharmaceutical companies, will gain both oral and injectable assets as a result of this acquisition.

"This practice has been adopted by multiple organ-procurement organizations and is used on thousands of organ donors each year, without ever having been rigorously studied," one researcher said. 

GLP-1 agonists are often taken as daily or weekly injections. A new delivery system could help make it so those same drugs are only required three times per year.